TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
Chapter 6. Global Clinical Trials Market, by Phase
6.1 Introduction
6.2 Phase I
6.3 Phase II
6.4 Phase III
6.5 Phase IV
Chapter 7. Global Clinical Trials Market, by Study Design
7.1 Introduction
7.2 Interventional
7.3 Observational
7.4 Expanded Access
Chapter 8. Global Clinical Trials Market, by Indication
8.1 Introduction
8.2 Autoimmune/inflammation
8.3 Pain management
8.4 Oncology
8.5 CNS condition
8.6 Diabetes
8.7 Obesity
8.8 Cardiovascular
8.9 Others
Chapter 9. Global Clinical Trials Market, by End User
9.1 Introduction
9.2 Medical Institutes
9.3 Hospitals and Clinics
9.4 Others
Chapter 10. Global Clinical Trials Market, by Region
10.1 Introduction
10.2 America
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 Latin America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 U. K
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia-Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
Chapter 11. Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 12 Company Profiles
12.1 Quintiles IMS
12.1.1 Company Overview
12.1.2 Overview
12.1.3 Financials
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.2 Paraxel International Corporation
12.2.1 Company Overview
12.2.2 Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Charles River Laboratories
12.3.1 Company Overview
12.3.2 Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 ICON plc
12.4.1 Company Overview
12.4.2 Phase /Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 SGS SA
12.5.1 Company Overview
12.5.2 Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.6 Eli Lilly and Company
12.6.1 Company Overview
12.6.2 Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.7 Novo Nordisk A/S
12.7.1 Overview
12.7.2 Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Clinipace
12.8.1 Overview
12.8.2 Overview
12.8.3 Financials
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.9 Laboratory Corporation of America
12.9.1 Overview
12.9.2 Overview
12.9.3 Financials
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.10 Pfizer
12.10.1 Overview
12.10.2 Overview
12.10.3 Financials
12.10.4 Key Developments
12.10.5 SWOT Analysis
Chapter 13. Appendix
LIST OF TABLES
Table 1 Global Clinical Trials Synopsis, 2020–2027
Table 2 Global Clinical Trials Market Estimates and Forecast, 2020–2027, (USD Million)
Table 3 Global Clinical Trials Market by Region, 2020–2027, (USD Million)
Table 4 Global Clinical Trials Market by Phase, 2020–2027, (USD Million)
Table 5 Global Clinical Trials Market by Study Design, 2020–2027, (USD Million)
Table 6 Global Clinical Trials Market by Indication, 2020–2027, (USD Million)
Table 7 Global Clinical Trials Market by Indication, 2020–2027, (USD Million)
Table 8 North America Clinical Trials Market by Phase, 2020–2027, (USD Million)
Table 9 North America Clinical Trials Market by Study Design, 2020–2027, (USD Million)
Table 10 North America Clinical Trials Market by Indication, 2020–2027, (USD Million)
Table 11 North America Clinical Trials Market by End User, 2020–2027, (USD Million)
Table 12 U.S. Clinical Trials Market by Phase, 2020–2027, (USD Million)
Table 13 U.S. Clinical Trials Market by Study Design, 2020–2027, (USD Million)
Table 14 U.S. Clinical Trials Market by Indication, 2020–2027, (USD Million)
Table 15 U.S. Clinical Trials Market by End User, 2020–2027, (USD Million)
Table 16 Canada Clinical Trials Market by Phase, 2020–2027, (USD Million)
Table 17 Canada Clinical Trials Market by Study Design, 2020–2027, (USD Million)
Table 18 Canada Clinical Trials Market by Indication, 2020–2027, (USD Million)
Table 19 Canada Clinical Trials Market by End User, 2020–2027, (USD Million)
Table 20 Latin America Clinical Trials Market by Phase, 2020–2027, (USD Million)
Table 21 Latin America Clinical Trials Market by Study Design, 2020–2027, (USD Million)
Table 22 Latin America Clinical Trials Market by Indication, 2020–2027, (USD Million)
Table 23 Latin America Clinical Trials Market by End User, 2020–2027, (USD Million)
Table 24 Europe Clinical Trials Market by Phase, 2020–2027, (USD Million)
Table 25 Europe Clinical Trials Market by Study Design, 2020–2027, (USD Million)
Table 26 Europe Clinical Trials Market by Indication, 2020–2027, (USD Million)
Table 27 Europe Clinical Trials Market by End User, 2020–2027, (USD Million)
Table 28 Western Europe Clinical Trials Market by Phase, 2020–2027, (USD Million)
Table 29 Western Europe Clinical Trials Market by Study Design, 2020–2027, (USD Million)
Table 30 Western Europe Clinical Trials Market by Indication, 2020–2027, (USD Million)
Table 31 Western Europe Clinical Trials Market by End User, 2020–2027, (USD Million)
Table 32 Eastern Europe Clinical Trials Market by Phase, 2020–2027, (USD Million)
Table 33 Eastern Europe Clinical Trials Market by Study Design, 2020–2027, (USD Million)
Table 34 Eastern Europe Clinical Trials Market by Indication, 2020–2027, (USD Million)
Table 35 Eastern Europe Clinical Trials Market by End User, 2020–2027, (USD Million)
Table 36 Asia-Pacific Clinical Trials Market by Phase, 2020–2027, (USD Million)
Table 37 Asia-Pacific Clinical Trials Market by Study Design, 2020–2027, (USD Million)
Table 38 Asia-Pacific Clinical Trials Market by Indication, 2020–2027, (USD Million)
Table 39 Asia-Pacific Clinical Trials Market by End User, 2020–2027, (USD Million)
Table 40 Middle East & Africa Clinical Trials Market by Phase, 2020–2027, (USD Million)
Table 41 Middle East & Africa Clinical Trials Market by Study Design, 2020–2027, (USD Million)
Table 42 Middle East & Africa Clinical Trials Market by Indication, 2020–2027, (USD Million)
Table 43 Middle East & Africa Clinical Trials Market by End User, 2020–2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Clinical Trials Market
Figure 3 Segmentation Market Dynamics for Global Clinical Trials Market
Figure 4 Global Clinical Trials Market Share, by Phase, 2020
Figure 5 Global Clinical Trials Market Share, by Study Design, 2020
Figure 6 Global Clinical Trials Market Share, by Indication, 2020
Figure 7 Global Clinical Trials Market Share, by End User, 2020
Figure 8 Global Clinical Trials Market Share, by Region, 2020
Figure 9 North America Clinical Trials Market Share, by Country, 2020
Figure 10 Europe Clinical Trials Market Share, by Country, 2020
Figure 11 Asia-Pacific Clinical Trials Market Share, by Country, 2020
Figure 12 Middle East & Africa Clinical Trials Market Share, by Country, 2020
Figure 13 Global Clinical Trials Market: Company Share Analysis, 2020 (%)
Figure 14 Quintiles IMS: Key Financials
Figure 15 Quintiles IMS: Segmental Revenue
Figure 16 Quintiles IMS: Geographical Revenue
Figure 17 Paraxel International Corporation: Key Financials
Figure 18 Paraxel International Corporation: Segmental Revenue
Figure 19 Paraxel International Corporation: Geographical Revenue
Figure 20 Charles River Laboratories: Key Financials
Figure 21 Charles River Laboratories: Segmental Revenue
Figure 22 Charles River Laboratories: Geographical Revenue
Figure 23 ICON plc: Key Financials
Figure 24 ICON plc: Segmental Revenue
Figure 25 ICON plc: Geographical Revenue
Figure 26 SGS SA: Key Financials
Figure 27 SGS SA: Segmental Revenue
Figure 28 SGS SA: Geographical Revenue
Figure 29 Eli Lilly and Company: Key Financials
Figure 30 Eli Lilly and Company: Segmental Revenue
Figure 31 Eli Lilly and Company: Geographical Revenue
Figure 32 Novo Nordisk A/S: Key Financials
Figure 33 Novo Nordisk A/S: Segmental Revenue
Figure 34 Novo Nordisk A/S: Geographical Revenue
Figure 35 Clinipace: Key Financials
Figure 36 Clinipace: Segmental Revenue
Figure 37 Clinipace: Geographical Revenue
Figure 38 Laboratory Corporation of America: Key Financials
Figure 39 Laboratory Corporation of America: Segmental Revenue
Figure 40 Laboratory Corporation of America: Geographical Revenue
Figure 41 Pfizer: Key Financials
Figure 42 Pfizer: Segmental Revenue
Figure 43 Pfizer: Geographical Revenue
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
